메뉴 건너뛰기




Volumn 11, Issue , 2015, Pages 271-282

Current and emerging strategies in the management of venous thromboembolism: Benefit–risk assessment of dabigatran

Author keywords

Dabigatran; Deep venous thrombosis; Novel oral anticoagulants; Oral anticoagulation; Pulmonary embolism; Venous thromboembolism

Indexed keywords

APIXABAN; BLOOD CLOTTING FACTOR 7; DABIGATRAN ETEXILATE; ENOXAPARIN; FONDAPARINUX; HEPARIN; IDARUCIZUMAB; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTHROMBIN COMPLEX; RIVAROXABAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN; DABIGATRAN; VITAMIN K GROUP;

EID: 84936750000     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S62595     Document Type: Review
Times cited : (10)

References (63)
  • 1
    • 70350551984 scopus 로고    scopus 로고
    • Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study
    • Spencer FA, Emery C, Joffe SW, et al. Incidence rates, clinical profile, and outcomes of patients with venous thromboembolism. The Worcester VTE study. J Thromb Thrombolysis. 2009;28(4):401–409.
    • (2009) J Thromb Thrombolysis , vol.28 , Issue.4 , pp. 401-409
    • Spencer, F.A.1    Emery, C.2    Joffe, S.W.3
  • 2
    • 0033535363 scopus 로고    scopus 로고
    • Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study
    • Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort study. Arch Intern Med. 2009;159(5):445–453.
    • (2009) Arch Intern Med , vol.159 , Issue.5 , pp. 445-453
    • Heit, J.A.1    Silverstein, M.D.2    Mohr, D.N.3    Petterson, T.M.4    O’Fallon, W.M.5    Melton, L.J.6
  • 3
    • 45949108549 scopus 로고    scopus 로고
    • American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines
    • (8th edition)
    • Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ; American College of Chest Physicians. Antithrombotic and thrombolytic therapy: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):110S–112S.
    • (2008) Chest , vol.133 , Issue.6 , pp. 110S-112S
    • Hirsh, J.1    Guyatt, G.2    Albers, G.W.3    Harrington, R.4    Schünemann, H.J.5
  • 4
    • 0037704209 scopus 로고    scopus 로고
    • Natural history of venous thromboembolism
    • Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107(23 Suppl 1):1–22.
    • (2003) Circulation , vol.107 , Issue.23 , pp. 1-22
    • Kearon, C.1
  • 5
    • 84055189856 scopus 로고    scopus 로고
    • Evidence-based venous thromboembolism prophylaxis is associated with a six-fold decrease in numbers of symptomatic venous thromboembolisms in rehabilitation inpatients
    • Mayer RS, Streiff MB, Hobson DB, Halpert DE, Berenholtz SM. Evidence-based venous thromboembolism prophylaxis is associated with a six-fold decrease in numbers of symptomatic venous thromboembolisms in rehabilitation inpatients. PM R. 2011;3(12):1111–1115.
    • (2011) PM R , vol.3 , Issue.12 , pp. 1111-1115
    • Mayer, R.S.1    Streiff, M.B.2    Hobson, D.B.3    Halpert, D.E.4    Berenholtz, S.M.5
  • 6
    • 38649115655 scopus 로고    scopus 로고
    • ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): A multinational cross-sectional study
    • Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387–394.
    • (2008) Lancet , vol.371 , Issue.9610 , pp. 387-394
    • Cohen, A.T.1    Tapson, V.F.2    Bergmann, J.F.3
  • 7
    • 84856802635 scopus 로고    scopus 로고
    • American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis
    • 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Kearon C, Akl EA, Comerota AJ, et al; American College of Chest Physicians. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):419S–494S.
    • (2012) Chest , vol.141 , Issue.2 , pp. 419S-494S
    • Kearon, C.1    Akl, E.A.2    Comerota, A.J.3
  • 8
    • 45949103309 scopus 로고    scopus 로고
    • Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines
    • Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6 Suppl):160S–198S.
    • (2008) Chest , vol.133 , Issue.6 , pp. 160S-198S
    • Ansell, J.1    Hirsh, J.2    Hylek, E.3    Jacobson, A.4    Crowther, M.5    Palareti, G.6
  • 9
    • 58749095297 scopus 로고    scopus 로고
    • Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation
    • Eckman MH, Rosand J, Greenberg SM, Gage BF. Cost-effectiveness of using pharmacogenetic information in warfarin dosing for patients with nonvalvular atrial fibrillation. Ann Intern Med. 2009;150(2):73–83.
    • (2009) Ann Intern Med , vol.150 , Issue.2 , pp. 73-83
    • Eckman, M.H.1    Rosand, J.2    Greenberg, S.M.3    Gage, B.F.4
  • 10
    • 77955872745 scopus 로고    scopus 로고
    • A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey
    • Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138(5):1093–1100.
    • (2010) Chest , vol.138 , Issue.5 , pp. 1093-1100
    • Pisters, R.1    Lane, D.A.2    Nieuwlaat, R.3    De Vos, C.B.4    Crijns, H.J.5    Lip, G.Y.6
  • 11
    • 23344449367 scopus 로고    scopus 로고
    • Duration of anticoagulation following venous thromboembolism: A meta-analysis
    • Ost D, Tepper J, Mihara H, Lander O, Heinzer R, Fein A. Duration of anticoagulation following venous thromboembolism: a meta-analysis. JAMA. 2005;294(6):706–715.
    • (2005) JAMA , vol.294 , Issue.6 , pp. 706-715
    • Ost, D.1    Tepper, J.2    Mihara, H.3    Lander, O.4    Heinzer, R.5    Fein, A.6
  • 12
    • 81855169543 scopus 로고    scopus 로고
    • Emergency hospitalizations for adverse drug events in older Americans
    • Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365(21):2002–2012.
    • (2011) N Engl J Med , vol.365 , Issue.21 , pp. 2002-2012
    • Budnitz, D.S.1    Lovegrove, M.C.2    Shehab, N.3    Richards, C.L.4
  • 13
    • 84856797169 scopus 로고    scopus 로고
    • Prevention of VTE in orthopedic surgery patients: Antithrombotic therapy and prevention of thrombosis
    • 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl): 278S–325S.
    • (2012) Chest , vol.141 , Issue.2 , pp. 278S-325S
    • Falck-Ytter, Y.1    Francis, C.W.2    Johanson, N.A.3
  • 14
    • 18744433904 scopus 로고    scopus 로고
    • Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison. North American Fragmin trial investigators
    • Hull RD, Pineo GF, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin trial investigators. Arch Intern Med. 2000;160(14):2208–2215.
    • (2000) Arch Intern Med , vol.160 , Issue.14 , pp. 2208-2215
    • Hull, R.D.1    Pineo, G.F.2    Francis, C.3
  • 15
    • 46049090201 scopus 로고    scopus 로고
    • Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines
    • Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2008;133(6 Suppl):381S–453S.
    • (2008) Chest , vol.133 , Issue.6 , pp. 381S-453S
    • Geerts, W.H.1    Bergqvist, D.2    Pineo, G.F.3
  • 16
    • 77955575162 scopus 로고    scopus 로고
    • Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery
    • Wilke T, Moock J, Müller S, Pfannkuche M, Kurth A. Nonadherence in outpatient thrombosis prophylaxis with low molecular weight heparins after major orthopaedic surgery. Clin Orthop Relat Res. 2010;468(9): 2437–2453.
    • (2010) Clin Orthop Relat Res , vol.468 , Issue.9 , pp. 2437-2453
    • Wilke, T.1    Moock, J.2    Müller, S.3    Pfannkuche, M.4    Kurth, A.5
  • 17
    • 77953436481 scopus 로고    scopus 로고
    • Patient preferences for an oral anticoagulant after major orthopedic surgery: Results of a German survey
    • Wilke T. Patient preferences for an oral anticoagulant after major orthopedic surgery: results of a German survey. Patient. 2009;2(1):39–49.
    • (2009) Patient , vol.2 , Issue.1 , pp. 39-49
    • Wilke, T.1
  • 18
    • 77950880770 scopus 로고    scopus 로고
    • New anticoagulants
    • Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010; 121(13):1523–1532.
    • (2010) Circulation , vol.121 , Issue.13 , pp. 1523-1532
    • Eikelboom, J.W.1    Weitz, J.I.2
  • 19
    • 84859971651 scopus 로고    scopus 로고
    • New oral anticoagulants: A view from the laboratory
    • Weitz JI. New oral anticoagulants: a view from the laboratory. Am J Hematol. 2012;87(S1):S133–S136.
    • (2012) Am J Hematol , vol.87 , Issue.S1 , pp. S133-S136
    • Weitz, J.I.1
  • 20
    • 34548031359 scopus 로고    scopus 로고
    • The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
    • Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292–303.
    • (2007) Br J Clin Pharmacol , vol.64 , Issue.3 , pp. 292-303
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3    Gansser, D.4    Roth, W.5
  • 21
    • 38749131205 scopus 로고    scopus 로고
    • The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans
    • Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386–399.
    • (2008) Drug Metab Dispos , vol.36 , Issue.2 , pp. 386-399
    • Blech, S.1    Ebner, T.2    Ludwig-Schwellinger, E.3    Stangier, J.4    Roth, W.5
  • 23
    • 77952737706 scopus 로고    scopus 로고
    • Drug and dietary interactions of the new and emerging oral anticoagulants
    • Walenga JM, Adiguzel C. Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010;64(7):956–967.
    • (2010) Int J Clin Pract , vol.64 , Issue.7 , pp. 956-967
    • Walenga, J.M.1    Adiguzel, C.2
  • 24
    • 84936808352 scopus 로고    scopus 로고
    • Pradaxa® (Dabigatran) Package Insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc
    • Pradaxa® (Dabigatran) Package Insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2013.
    • (2013)
  • 25
    • 35449007749 scopus 로고    scopus 로고
    • RE-MODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial
    • Eriksson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007;5(11):2178–2185.
    • (2007) J Thromb Haemost , vol.5 , Issue.11 , pp. 2178-2185
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 26
    • 34548575058 scopus 로고    scopus 로고
    • RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Rosencher N, et al; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370(9591):949–956.
    • (2007) Lancet , vol.370 , Issue.9591 , pp. 949-956
    • Eriksson, B.I.1    Dahl, O.E.2    Rosencher, N.3
  • 27
    • 79953836474 scopus 로고    scopus 로고
    • RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: A randomised, double-blind, non-inferiority trial
    • Eriksson BI, Dahl OE, Huo MH, et al; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty: a randomised, double-blind, non-inferiority trial. Thromb Haemost. 2011;105(4):721–729.
    • (2011) Thromb Haemost , vol.105 , Issue.4 , pp. 721-729
    • Eriksson, B.I.1    Dahl, O.E.2    Huo, M.H.3
  • 28
    • 57649123692 scopus 로고    scopus 로고
    • Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery
    • RE-MOBILIZE Writing Committee
    • RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009;24:1–9.
    • (2009) J Arthroplasty , vol.24 , pp. 1-9
    • Ginsberg, J.S.1    Davidson, B.L.2
  • 29
    • 77953791161 scopus 로고    scopus 로고
    • RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
    • Friedman RJ, Dahl OE, Rosencher N, et al; RE-MOBILIZE, RE-MODEL, RE-NOVATE Steering Committees. Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res. 2010;126(3): 175–182.
    • (2010) Thromb Res , vol.126 , Issue.3 , pp. 175-182
    • Friedman, R.J.1    Dahl, O.E.2    Rosencher, N.3
  • 30
    • 71849117615 scopus 로고    scopus 로고
    • RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
    • (2009) N Engl J Med , vol.361 , Issue.24 , pp. 2342-2352
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 31
    • 84894295323 scopus 로고    scopus 로고
    • RE-COVER II Trial Investigators. Treatment of thromboembolism with dabigatran or warfarin and pooled analysis
    • Schulman S, Kakkar AK, Goldhaber SZ, et al; RE-COVER II Trial Investigators. Treatment of thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764–772.
    • (2014) Circulation , vol.129 , Issue.7 , pp. 764-772
    • Schulman, S.1    Kakkar, A.K.2    Goldhaber, S.Z.3
  • 32
    • 84874003257 scopus 로고    scopus 로고
    • RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism
    • Schulman S, Kearon C, Kakkar AK, et al; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709–718.
    • (2013) N Engl J Med , vol.368 , Issue.8 , pp. 709-718
    • Schulman, S.1    Kearon, C.2    Kakkar, A.K.3
  • 33
    • 70349306707 scopus 로고    scopus 로고
    • RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation
    • Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139–1151.
    • (2009) N Engl J Med , vol.361 , Issue.12 , pp. 1139-1151
    • Connolly, S.J.1    Ezekowitz, M.D.2    Yusuf, S.3
  • 35
    • 84911464122 scopus 로고    scopus 로고
    • Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: A systematic review and meta-analysis of randomized controlled trials
    • Douxfils J, Buckinx F, Mullier F, et al. Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2014;3(3):e000515.
    • (2014) J am Heart Assoc , vol.3 , Issue.3
    • Douxfils, J.1    Buckinx, F.2    Mullier, F.3
  • 36
    • 84857021520 scopus 로고    scopus 로고
    • Dabigatran association with higher risk of acute coronary events: Meta-analysis of noninferiority randomized controlled trials
    • Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397–402.
    • (2012) Arch Intern Med , vol.172 , Issue.5 , pp. 397-402
    • Uchino, K.1    Hernandez, A.V.2
  • 37
    • 84869795745 scopus 로고    scopus 로고
    • Coronary and mortality risk of novel oral antithrombotic agents: A meta-analysis of large randomised trials
    • Mak KH. Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials. BMJ Open. 2012;2(5):e001592.
    • (2012) BMJ Open , vol.2 , Issue.5
    • Mak, K.H.1
  • 38
    • 84936808353 scopus 로고    scopus 로고
    • University of Sao Paulo General Hospital. Effects of LMWH versus dabigatran on platelet aggregation in patients with stable coronary artery disease. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 20, 2015]. Available from
    • University of Sao Paulo General Hospital. Effects of LMWH versus dabigatran on platelet aggregation in patients with stable coronary artery disease. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT02389582.
  • 39
    • 84863600252 scopus 로고    scopus 로고
    • Thrombotic events after discontinuing dabigatran: Rebound or resumption?
    • Thorne KM, Dee S, Jayathissa S. Thrombotic events after discontinuing dabigatran: rebound or resumption? BMJ. 2012;345:e4469.
    • (2012) BMJ , vol.345
    • Thorne, K.M.1    Dee, S.2    Jayathissa, S.3
  • 40
    • 84862585771 scopus 로고    scopus 로고
    • A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: The randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)
    • Van de Werf F, Brueckmann M, Connolly SJ. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: the randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931–937.
    • (2012) Am Heart J , vol.163 , Issue.6 , pp. 931-937
    • Van De Werf, F.1    Brueckmann, M.2    Connolly, S.J.3
  • 41
    • 84904675268 scopus 로고    scopus 로고
    • Dabigatran, bleeding, and the regulators
    • Moore TJ, Cohen MR, Mattison DR. Dabigatran, bleeding, and the regulators. BMJ. 2014;349:g4517.
    • (2014) BMJ , vol.349
    • Moore, T.J.1    Cohen, M.R.2    Mattison, D.R.3
  • 42
    • 84893160985 scopus 로고    scopus 로고
    • RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: The RE-LY trial (randomized evaluation of long-term anticoagulation therapy)
    • Reilly PA, Lehr T, Haertter S, et al; RE-LY Investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol. 2014;63(4):321–328.
    • (2014) J am Coll Cardiol , vol.63 , Issue.4 , pp. 321-328
    • Reilly, P.A.1    Lehr, T.2    Haertter, S.3
  • 43
    • 77953168824 scopus 로고    scopus 로고
    • Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
    • van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116–1127.
    • (2010) Thromb Haemost , vol.103 , Issue.6 , pp. 1116-1127
    • Van Ryn, J.1    Stangier, J.2    Haertter, S.3
  • 44
    • 84906934289 scopus 로고    scopus 로고
    • Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays
    • van Ryn J, Grottke O, Spronk H. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays. Clin Lab Med. 2014;34(3):479–501.
    • (2014) Clin Lab Med , vol.34 , Issue.3 , pp. 479-501
    • Van Ryn, J.1    Grottke, O.2    Spronk, H.3
  • 45
    • 79954456496 scopus 로고    scopus 로고
    • Dabigatran etexilate: A new oral thrombin inhibitor
    • Hankey GJ, Eikelboom JW. Dabigatran etexilate: a new oral thrombin inhibitor. Circulation. 2011;123(13):1436–1450.
    • (2011) Circulation , vol.123 , Issue.13 , pp. 1436-1450
    • Hankey, G.J.1    Eikelboom, J.W.2
  • 46
    • 84936808354 scopus 로고    scopus 로고
    • In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 20, 2015]. Available from
    • Herrmann RP. Assays for and reversal of new anticoagulants. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT01795781.
    • Assays for and Reversal of New Anticoagulants
    • Herrmann, R.P.1
  • 47
    • 67849124919 scopus 로고    scopus 로고
    • Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VII
    • Van Ryn J, Ruehl D, Priepke H, Hauel N, Wienen W. Reversibility of the anticoagulant effect of high doses of the direct thrombin inhibitor dabigatran, by recombinant factor VII. Haematologica. 2008;93(Supple 1):148.
    • (2008) Haematologica , vol.93 , pp. 148
    • Van Ryn, J.1    Ruehl, D.2    Priepke, H.3    Hauel, N.4    Wienen, W.5
  • 48
    • 80053571188 scopus 로고    scopus 로고
    • Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects
    • Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–1579.
    • (2011) Circulation , vol.124 , Issue.14 , pp. 1573-1579
    • Eerenberg, E.S.1    Kamphuisen, P.W.2    Sijpkens, M.K.3    Meijers, J.C.4    Buller, H.R.5    Levi, M.6
  • 49
    • 84879548455 scopus 로고    scopus 로고
    • A specific antidote for dabigatran: Functional and structural characterization
    • Schiele F, van Ryn J, Newsome C, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013; 121(18):3554–3562.
    • (2013) Blood , vol.121 , Issue.18 , pp. 3554-3562
    • Schiele, F.1    Van Ryn, J.2    Newsome, C.3
  • 50
    • 84936808355 scopus 로고    scopus 로고
    • Effect of Dabigatran on the Ability to Generate Fibrin At a Wound Site and its Reversal By Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss
    • Chicago, USA
    • van Ryn J, Schmoll M, Pillu H, et al. Effect of Dabigatran on the Ability to Generate Fibrin At a Wound Site and its Reversal By Idarucizumab, the Antidote to Dabigatran, in Healthy Volunteers: An Exploratory Marker of Blood Loss. In: Presented on 18th November at the American Heart Association Scientific Sessions. Chicago, USA; 2014.
    • Presented on 18Th November at the American Heart Association Scientific Sessions , pp. 2014
    • Van Ryn, J.1    Schmoll, M.2    Pillu, H.3
  • 51
    • 84856784474 scopus 로고    scopus 로고
    • American College of Chest Physicians. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis
    • 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines
    • Ageno W, Gallus AS, Wittkowsky A, et al; American College of Chest Physicians. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl): 44S–88S.
    • (2012) Chest , vol.141 , Issue.2 , pp. 44S-88S
    • Ageno, W.1    Gallus, A.S.2    Wittkowsky, A.3
  • 52
    • 77949421739 scopus 로고    scopus 로고
    • Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate
    • Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate. Clin Pharmacokinet. 2010;49(4):259–268.
    • (2010) Clin Pharmacokinet , vol.49 , Issue.4 , pp. 259-268
    • Stangier, J.1    Rathgen, K.2    Stähle, H.3    Mazur, D.4
  • 54
    • 84874114340 scopus 로고    scopus 로고
    • Removal of dabigatran by hemodialysis
    • Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. Am J Kidney Dis. 2013;61(3):487–489.
    • (2013) Am J Kidney Dis , vol.61 , Issue.3 , pp. 487-489
    • Chang, D.N.1    Dager, W.E.2    Chin, A.I.3
  • 55
    • 84929510155 scopus 로고    scopus 로고
    • Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis
    • Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972–979.
    • (2015) Circulation , vol.131 , Issue.11 , pp. 972-979
    • Chan, K.E.1    Edelman, E.R.2    Wenger, J.B.3    Thadhani, R.I.4    Maddux, F.W.5
  • 56
    • 84889818750 scopus 로고    scopus 로고
    • The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation
    • Roldán V, Marín F, Manzano-Fernández S, et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–2204.
    • (2013) J am Coll Cardiol , vol.62 , Issue.23 , pp. 2199-2204
    • Roldán, V.1    Marín, F.2    Manzano-Fernández, S.3
  • 57
    • 84936808356 scopus 로고    scopus 로고
    • Capital District Health Authority. An evaluation of the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate in hemodialysis patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US), [cited April 20, 2015]. Available from
    • Capital District Health Authority. An evaluation of the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate in hemodialysis patients. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US); 2000 [cited April 20, 2015]. Available from: http://clinicaltrials.gov/show/NCT01590823.
    • (2000)
  • 58
    • 84857853180 scopus 로고    scopus 로고
    • Bleeding risk with dabigatran in the frail elderly
    • Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med. 2012;366(9):864–866.
    • (2012) N Engl J Med , vol.366 , Issue.9 , pp. 864-866
    • Harper, P.1    Young, L.2    Merriman, E.3
  • 59
    • 84924354347 scopus 로고    scopus 로고
    • Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants
    • Geldhof V, Vandenbriele C, Verhamme P, Vanassche T. Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J. 2014;12:21.
    • (2014) Thromb J , vol.12 , pp. 21
    • Geldhof, V.1    Vandenbriele, C.2    Verhamme, P.3    Vanassche, T.4
  • 60
    • 84924034859 scopus 로고    scopus 로고
    • Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation
    • Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly Medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2014;131:157–164.
    • (2014) Circulation , vol.131 , pp. 157-164
    • Graham, D.J.1    Reichman, M.E.2    Wernecke, M.3
  • 61
    • 84936773051 scopus 로고    scopus 로고
    • Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis
    • Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002;18:3078–3083.
    • (2002) Blood , vol.18 , pp. 3078-3083
    • Prandoni, P.1    Lensing, A.W.2    Piccioli, A.3
  • 62
    • 84873025833 scopus 로고    scopus 로고
    • International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer
    • Farge D, Debourdeau P, Beckers M, et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost. 2013;11(1):56–70.
    • (2013) J Thromb Haemost , vol.11 , Issue.1 , pp. 56-70
    • Farge, D.1    Debourdeau, P.2    Beckers, M.3
  • 63
    • 84934759278 scopus 로고    scopus 로고
    • Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer
    • Epub March 5
    • Schulman S, Goldhaber SZ, Kearon C, et al. Treatment with dabigatran or warfarin in patients with venous thromboembolism and cancer. Thromb Haemost. Epub March 5, 2015.
    • (2015) Thromb Haemost
    • Schulman, S.1    Goldhaber, S.Z.2    Kearon, C.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.